TU-BcX-4IC cells were sensitized to various anti-cancer drugs including bleomycin, HER inhibitors afatinib and lapatinib, ER inhibitor fulvestrant, MEK1/2 inhibitors trametinib and cobimetinib, and other targeted inhibitors (dabrafenib, everolimus, ponatinib, and crizotinib) following pre-treatment with romidepsin. This evidence concerns the gene MAP2K1 and cancer.